Status:
COMPLETED
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
Lead Sponsor:
Dr. Falk Pharma GmbH
Conditions:
Primary Biliary Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy of Ursofalk 500 mg tablets versus Ursofalk 500 mg capsules in the treatment of Primary Biliary Cirrhosis (PBC).
Eligibility Criteria
Inclusion
- Negative pregnancy
- Signed informed consent
- Histologically proven non-cirrhotic liver disease
Exclusion
- histologically proven cirrhosis
- PBC stage II+IV
- Positive HIV serology
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01510860
Start Date
November 1 2008
End Date
July 1 2010
Last Update
May 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Grosshadern
Munich, Germany, 81377